WFRF:(Rosendahl Ann H.)
Search: WFRF:(Rosendahl Ann H.) > (2015-2019) > Combined and indivi...
- 5 of 10
- Previous record
- Next record
- To hitlist
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 06083naa a2200469 4500 | |
| 001 | oai:lup.lub.lu.se:5b0f94a1-71f4-494a-9f53-c5da14f10c72 | |
| 003 | SwePub | |
| 008 | 170303s2017 | |||||||||||000 ||eng| | |
| 024 | 7 | a https://lup.lub.lu.se/record/5b0f94a1-71f4-494a-9f53-c5da14f10c722 URI |
| 024 | 7 | a https://doi.org/10.18632/oncotarget.140822 DOI |
| 040 | a (SwePub)lu | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a art2 swepub-publicationtype |
| 072 | 7 | a ref2 swepub-contenttype |
| 100 | 1 | a Björner, Sofieu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-snl |
| 245 | 1 0 | a Combined and individual tumor-specific expression of insulinlike growth factor-I receptor, insulin receptor and phosphoinsulin- like growth factor-I receptor/insulin receptor in primary breast cancer : Implications for prognosis in different treatment groups |
| 264 | c 2016-12-21 | |
| 264 | 1 | b Impact Journals, LLC,c 2017 |
| 300 | a 15 s. | |
| 520 | a Clinical trials examining insulin-like growth factor-I receptor (IGF1R)-targeting strategies have emphasized that better predictive biomarkers are required to improve patient selection. Immunohistochemical tumor-specific protein expression of IGF1R, insulin receptor (InsR), and phosphorylated IGF1R/InsR (pIGF1R/InsR) individually and combined in relation to breast cancer prognosis was evaluated in a populationbased cohort of 1,026 primary invasive breast cancer patients without preoperative treatment diagnosed in Sweden. IGF1R (n = 923), InsR (n = 900), and pIGF1R/InsR (n = 904) combined cytoplasmic and membrane staining was dichotomized. IGF1Rstrong/InsRmod/strong/pIGF1R/InsRpos tumors were borderline associated with 2-fold risk for events, HRadj (2.00; 95%CI 0.96-4.18). Combined IGF1R and pIGF1R/InsR status only impacted prognosis in patients with InsRmod/strong expressing tumors (Pinteraction = 0.041). IGF1Rstrong expression impacted endocrine treatment response differently depending on patients' age and type of endocrine therapy. Phospho-IGF1R/InsRpos was associated with lower risk for events among non-endocrine-treated patients irrespective of ER status, HRadj (0.32; 95%CI 0.16-0.63), but not among endocrinetreated patients (Pinteraction = 0.024). In non-endocrine-treated patients, pIGF1R/InsRpos was associated with lower risk for events after radiotherapy, HRadj (0.31; 95%CI 0.12-0.80), and chemotherapy, HRadj (0.29; 95%CI 0.09-0.99). This study highlights the complexity of IGF hetero-and homodimer signaling network and its interplay with endocrine treatment, suggesting that combinations of involved factors may improve patient selection for IGF1R-targeted therapy. | |
| 650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
| 650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
| 653 | a Breast cancer | |
| 653 | a Insulin receptor | |
| 653 | a Insulin-like growth factor-I receptor | |
| 653 | a Phospho-insulin-like growth factor-I receptor/insulin receptor | |
| 653 | a Prognosis | |
| 700 | 1 | a Rosendahl, Ann H.u Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-aro |
| 700 | 1 | a Simonsson, Mariau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-ms18 |
| 700 | 1 | a Markkula, Andreau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-am5 |
| 700 | 1 | a Jirström, Karinu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)pat-kji |
| 700 | 1 | a Borgquist, Signeu Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital4 aut0 (Swepub:lu)ront-sbo |
| 700 | 1 | a Rose, Carstenu Lund University,Lunds universitet,Create Health,Annan verksamhet, LTH,Lunds Tekniska Högskola,Institutionen för immunteknologi,Institutioner vid LTH,Other operations, LTH,Faculty of Engineering, LTH,Department of Immunotechnology,Departments at LTH,Faculty of Engineering, LTH4 aut0 (Swepub:lu)onk-cro |
| 700 | 1 | a Ingvar, Christianu Lund University,Lunds universitet,Kirurgi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Surgery (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)kir-cin |
| 700 | 1 | a Jernström, Helenau Lund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)onk-hje |
| 710 | 2 | a Tumörmikromiljöb Sektion I4 org |
| 773 | 0 | t Oncotargetd : Impact Journals, LLCg 8:6, s. 9093-9107q 8:6<9093-9107x 1949-2553 |
| 856 | 4 | u http://dx.doi.org/10.18632/oncotarget.14082x freey FULLTEXT |
| 856 | 4 | u http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=14082&path%5B%5D=44909 |
| 856 | 4 8 | u https://lup.lub.lu.se/record/5b0f94a1-71f4-494a-9f53-c5da14f10c72 |
| 856 | 4 8 | u https://doi.org/10.18632/oncotarget.14082 |
- 5 of 10
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Björner, Sofie
- Rosendahl, Ann H ...
- Simonsson, Maria
- Markkula, Andrea
- Jirström, Karin
- Borgquist, Signe
- show more...
- Rose, Carsten
- Ingvar, Christia ...
- Jernström, Helen ...
- show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Cancer and Oncol ...
- Articles in the publication
- Oncotarget
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
